To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for the expanded indication of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity in adults and children aged 4 and older [1][2] Company Overview - PANTHERx Rare specializes in patient access and support services for personalized rare disease care, focusing on making complex therapies more accessible through individualized case management and comprehensive support [1][2] - Since its founding in 2011, PANTHERx has grown to become the largest independent rare pharmacy in the U.S., maintaining a balance between established resources and small-company responsiveness [2][3] Product and Indication Details - IMCIVREE is indicated for chronic weight management in patients aged 2 years and older with obesity due to specific genetic conditions, including Bardet-Biedl Syndrome and deficiencies in POMC, PCSK1, or LEPR [2] - Acquired hypothalamic obesity is characterized by accelerated weight gain due to hypothalamic injury, often resulting from tumors or other neurological conditions [4] Collaboration and Support - The partnership with Rhythm Pharmaceuticals aims to provide high-touch clinical support to patients navigating treatment for acquired hypothalamic obesity, which has historically had limited therapeutic options [2] - PANTHERx employs its proprietary RxARECARE model to enhance patient and caregiver support, ensuring a personalized approach to therapy management [1][2]

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelanotide across 4 substudies of rare, genetically driven obesity. The trial did not meet its pre-specified primary endpoints, which measured the difference in mean percent change in BMI (body mass index) compared to a placebo over 52 weeks. While the primary analysis did no ...

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

Rhythm Pharmaceuticals Stock Pops; Imcivree Gets Approval Where GLP-1s Have 'Fallen Flat' | Investor's Business Daily MUTUAL FUNDS: How Top Funds Deliver Market-Beating Returns Rhythm Pharmaceuticals (RYTM) stock popped Friday after the Food and Drug Administration signed off on its obesity drug for patients with a rare, hunger-spiking disease. The company's Imcivree already has approval for a pool of roughly 7,500 patients in the U.S. with genetically driven forms of obesity. Now, the new approval in patie ...

Group 1 - The conference call is hosted by Rhythm Pharmaceuticals, indicating a focus on investor relations and communication with stakeholders [1] - David Connolly is the first speaker, suggesting a structured approach to the presentation with designated roles [1]

Rhythm Pharmaceuticals Conference Call Summary Company Overview - **Company**: Rhythm Pharmaceuticals (NasdaqGM:RYTM) - **Product**: IMCIVREE (setmelanotide) - **Indication**: Approved for patients with acquired hypothalamic obesity Key Points FDA Approval and Product Details - The FDA has granted approval for IMCIVREE to treat acquired hypothalamic obesity, marking it as the first FDA-approved therapy targeting the underlying biology of this condition [2][4] - IMCIVREE is a melanocortin 4 receptor (MC4R) agonist indicated to reduce excess body weight and maintain long-term weight reduction in adults and pediatric patients aged 4 and older [6] - The approval was supported by the global phase 3 TRANSCEND trial, which showed a statistically significant placebo-adjusted difference of 18.4% in BMI reduction after 52 weeks of treatment [7] Clinical Trial Results - The trial included a total of 142 patients, with significant improvements in hunger scores observed: a 2.3-point reduction in the treatment group compared to a 1.4-point reduction in the placebo group [7] - The consistent response to MC4R agonists across trials reinforces the importance of the MC4R pathway in the biology of obesity [5][9] Market Opportunity - Approximately 10,000 patients in the U.S. are estimated to have acquired hypothalamic obesity, with about 500 new cases annually [12] - The approval is expected to drive increased diagnosis rates and treatment initiation, as there was previously no approved treatment for this condition [12][13] Sales and Marketing Strategy - Rhythm has expanded its sales team from 16 to 42 territory managers to engage with physicians and secure reimbursement for patients [13] - The company aims to educate healthcare providers about the condition and the new treatment option, facilitating quicker diagnoses and treatment initiation [15][51] Payer Engagement and Reimbursement - Rhythm is working to differentiate IMCIVREE from other anti-obesity medications to improve coverage prospects with payers, including Medicare [8][68] - The company plans to provide metrics on patient start forms, payer coverage, and physician engagement as part of their launch strategy [28] Future Developments - Rhythm is pursuing international opportunities and anticipates updates on its Japanese filing and EMEA submission for hypothalamic obesity in the coming quarters [9] - The company is also working on obtaining an ICD-10 code for hypothalamic obesity to facilitate diagnosis and treatment [56] Safety and Monitoring - The approval includes a warning for monitoring adrenal insufficiency, as a significant portion of patients may have hormonal deficiencies [80] - The FDA did not allow the inclusion of hyperphagia reduction in the indication statement, although it is noted in the clinical results section [82][86] Conclusion - The approval of IMCIVREE represents a significant milestone for patients with acquired hypothalamic obesity, providing a much-needed treatment option and addressing a high unmet need in this patient population [88]

Core Viewpoint - Rhythm Pharmaceuticals has received FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, marking it as the first and only FDA-approved therapy for this condition [7][9]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE designed to treat hyperphagia and severe obesity [16]. - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity [9][15]. Product Details - IMCIVREE is indicated for reducing excess body weight and maintaining long-term weight reduction in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity [17]. - The approval is based on the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) [6][10]. Clinical Trial Results - In the TRANSCEND trial, participants on setmelanotide achieved a -15.8% reduction in BMI compared to a +2.6% increase in the placebo group at 52 weeks [10]. - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [10][27]. Market Implications - The approval of IMCIVREE addresses a critical unmet need for patients with acquired hypothalamic obesity, providing a targeted therapy that addresses the underlying biology of the disease [9][10]. - The company is committed to supporting patient access to IMCIVREE through programs like Rhythm InTune, which offers educational support and assistance with insurance navigation [12].

Core Insights - Rhythm Pharmaceuticals has received FDA approval for IMCIVREE® (setmelanotide) as the first and only therapy for acquired hypothalamic obesity, a rare condition leading to significant weight gain due to hypothalamic injury or dysfunction [2][4][10] - The approval is based on the results from the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) among participants [3][5][6] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with IMCIVREE as its lead asset [11] - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity, highlighting a significant unmet medical need [4][10] Product Details - IMCIVREE is indicated for adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, aiming to reduce excess body weight and maintain long-term weight reduction [3][12] - The therapy has also been approved for syndromic or monogenic obesity due to conditions such as Bardet-Biedl syndrome and POMC deficiency in patients aged 2 years and older [11][13] Clinical Trial Results - The Phase 3 TRANSCEND trial involved 142 patients, where those treated with setmelanotide achieved a -15.8% reduction in mean BMI compared to a +2.6% increase in the placebo group at 52 weeks [5][6] - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [5][21] Support and Access - Rhythm Pharmaceuticals is committed to ensuring patient access to IMCIVREE, with a support program called Rhythm InTune that provides educational resources and assistance with insurance navigation [7] - The company will host a conference call to discuss the FDA approval and its implications for patients and healthcare providers [8]

We recently compiled a list of the Top 10 Boring Stocks That Make Money. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most boring stocks that make money. TheFly reported on March 12 that Wells Fargo increased its price target for RYTM to $143 from $136 while keeping an Overweight rating on the stock. The update reflects slightly higher revenue projections and greater confidence in the launch of IMCIVREE for hypothalamic obesity. Discussions with physicians treating early patient populations po ...